Here's what we'll cover
Here's what we'll cover
If you've looked into Ozempic and immediately felt the sticker shock, you're not alone. For millions of Americans, the price of GLP-1 medications is the single biggest barrier to treatment. California lawmakers are now trying to do something about it, though not in the way many headlines suggested.
Senate Bill 1089, the Preventive Treatment Health Care Act, started as a sweeping proposal to require coverage of GLP-1 drugs for weight loss. It was scaled back, and Governor Gavin Newsom signed the final version into law on September 28, 2026. The law directs the state to pursue a partnership with a drug manufacturer through CalRx, the state's program for lower cost drugs, to increase competition, lower prices, and address potential shortages for at least one FDA approved GLP-1 medication used to treat obesity. It does not set a price, and no CalRx GLP-1 is available yet.
Here's what you need to know, whether you live in California or not.
What SB 1089 Actually Does
The original bill would have required California Public Employees' Retirement System (CalPERS) health plans, which cover about 1.3 million public employees and retirees, to include at least one GLP-1 medication for weight management. CalPERS opposed that version and estimated it would raise premiums by roughly $28 per member per month. That requirement was dropped as the bill moved through the legislature.
What became law is a price focused approach. The law has the state pursue a manufacturing or purchasing partnership under CalRx to make a GLP-1 available at a much lower cost, in the same way California has pursued lower cost insulin. It does not, by itself, require private insurers to cover obesity medications.
Why This Matters Beyond California
California is the largest state market in the country, and what it tries often gets copied. A state run effort to bring GLP-1 prices down would be closely watched by other states and by insurers. Several other states, including New Hampshire, Pennsylvania, Massachusetts, and South Carolina, have also recently ended Medicaid coverage of GLP-1s used only for weight loss, so cost is a live issue well beyond California.
Why California Is Focused on Price
Costs explain the shift. State data show prescriptions for GLP-1s used solely for weight loss jumped from about 20,000 to about 700,000 between 2018 and 2023 across Medi-Cal and commercial plans. In 2023, California spent about $416.8 million on those prescriptions in Medi-Cal, and commercial payers spent about $405.2 million.
Facing budget pressure, California ended Medi-Cal coverage of GLP-1s for obesity in 2026. The program still pays for certain GLP-1s when they are prescribed for type 2 diabetes. That decision is a major reason lawmakers moved from a coverage mandate toward a price reduction strategy.
The Real Cost Problem with GLP-1 Medications
To understand why this matters, you need to understand how expensive these drugs have been without coverage.
The list price of Wegovy (semaglutide, 2.4 mg) is about $1,349 per month. Ozempic, which is approved for type 2 diabetes but widely prescribed off label for weight loss, runs close to $1,000 per month. Mounjaro (tirzepatide) lists at about $1,112 per month, according to Eli Lilly.
List price is no longer the whole story, though. Both manufacturers now sell directly to cash paying patients at lower prices, which has changed the math for people without coverage.
Self pay prices have changed several times, so confirm them on the manufacturer sites. Even so, most patients take these medications long term, and a monthly cost of several hundred dollars is still out of reach for many households.
Even patients with insurance often run into roadblocks. Many commercial plans exclude weight loss drugs from their formularies, meaning the medication simply isn't covered regardless of medical need. Others require extensive prior authorization, documented diet attempts, or a specific BMI threshold before approving coverage. KFF's 2025 survey found only about 19% of large employers offering health benefits covered GLP-1s for weight loss.
Who Could Benefit
If a state negotiated price is achieved, the people most likely to benefit are those paying out of pocket.
The state has not released eligibility rules yet, but under the current CalRx model a product would be available to Californians with a prescription regardless of their insurance type.
Californians without coverage for weight loss medications, including former Medi-Cal enrollees who lost coverage in 2026, could see a lower cost option become available.
Public employees whose health plans do not cover GLP-1s for obesity could gain access to a lower priced supply, even without a coverage mandate.
People with obesity related conditions like prediabetes, sleep apnea, high blood pressure, or elevated cardiovascular risk are a large group that could gain from more affordable treatment. Studies in the New England Journal of Medicine have shown semaglutide producing average weight loss of around 15% of body weight over 68 weeks.
It's worth noting that nothing in this bill changes how self funded employer plans work. Those plans, which cover many workers at larger companies, are governed by federal law rather than state law.
The Insurance Coverage Gap: Why It Exists
Insurance companies have traditionally classified obesity medications as "lifestyle drugs," placing them in the same category as cosmetic procedures. This classification has allowed insurers to exclude them from standard coverage.
That framing is increasingly out of step with the science. Obesity is now understood as a complex chronic disease influenced by genetics, hormones, gut microbiome composition, and environmental factors, and the American Medical Association recognizes it as a disease. Recent FDA approvals, including Wegovy's expanded approval for cardiovascular risk reduction in 2024, have strengthened the argument that these medications serve a genuine medical purpose beyond aesthetics.
The coverage gap is wide, and the SB 1089 debate shows how hard it is to close. Supporters point to health benefits. Plans and budget officials point to premiums and state costs.
What Happens While You Wait for Legislation
Now that SB 1089 is law, any CalRx partnership still has to be negotiated and launched. For context, it took California about three years to bring its $55 CalRx insulin to market. And if you're outside California, you may be waiting even longer for anything similar. In the meantime, there are real options available to reduce your costs.
Manufacturer Self Pay and Savings Programs
Both Novo Nordisk (maker of Ozempic and Wegovy) and Eli Lilly (maker of Mounjaro and Zepbound) offer direct to patient self pay pricing, and savings cards for eligible commercially insured patients. The savings cards typically don't apply to government insurance like Medicaid or Medicare.
Compounded Semaglutide and Tirzepatide
During periods when brand name GLP-1 drugs faced supply shortages, the FDA allowed compounding pharmacies to produce versions of the active ingredients. That window has narrowed as shortages ended, and the rules have been changing. If you use a compounded product, verify that the pharmacy is state licensed and works with licensed prescribers, and ask your provider what happens if availability changes. You can check GLP-1 Coupons for current savings options.
Telehealth Providers and Subscription Models
Several telehealth platforms offer GLP-1 prescriptions at monthly prices that include the medication, consultation, and follow up care. These bundled models can be more cost effective than going through a traditional pharmacy without insurance. Compare options at Best Providers.
Appealing a Denial
If your insurer has denied coverage for a GLP-1 medication, you have the right to appeal. Your doctor can submit a letter of medical necessity documenting your BMI, related conditions, and previous weight loss attempts. Denials are sometimes overturned, especially when there is a clear clinical case.
What Advocates and Critics Are Saying
Supporters of state action argue that denying coverage for obesity treatment is both medically inconsistent and unfair. They point out that the long term costs of untreated obesity, including hospitalizations, cardiovascular events, and diabetes management, can exceed the cost of prevention through medication. Groups including the American Diabetes Association and the California Academy of Family Physicians supported SB 1089.
Critics, including CalPERS and some budget watchers, raise concerns about the cost to public plans and the potential for premiums to rise if coverage is mandated. California's Medi-Cal program already faced budget pressure, which is why it ended obesity coverage. A UC Berkeley analysis of the bill also noted that a measure limited to public employees could widen disparities, since it would not reach other commercial or Medi-Cal enrollees.
Some economists argue the math favors coverage once you account for reduced hospitalizations and better long term health outcomes. But those savings play out over years, while the medication costs hit immediately. The debate mirrors a broader national conversation about how the U.S. healthcare system values prevention versus treatment.
Where This Bill Stands and What Comes Next
Governor Newsom signed SB 1089 on September 28, 2026. The law authorizes the partnership but does not set a price or a timeline, and the state has not yet named a manufacturer partner or released eligibility details. Expect any CalRx GLP-1 product to take time, based on how long the state's insulin effort took.
If you're tracking this issue, it's also worth following the California Department of Managed Health Care, which oversees most state regulated health plans, and the state's CalRx program announcements.
No waiting list. No insurance needed.
Frequently Asked Questions
Will the California bill make Ozempic free or cheaper?
No. SB 1089, signed into law on September 28, 2026, directs the state to pursue a manufacturer partnership through CalRx to lower GLP-1 prices, but it does not set a price. California's CalRx insulin took about three years to reach the market, so a GLP-1 product could also take time.
Does Medi-Cal currently cover Ozempic or Wegovy?
Medi-Cal ended coverage of GLP-1s for obesity in 2026 because of cost pressures. It still covers certain GLP-1s, such as Ozempic, when they are prescribed for type 2 diabetes. SB 1089 does not restore Medi-Cal coverage for weight loss.
What if I live outside California? Will this bill help me?
The bill directly affects California only. However, California often influences national policy, and a state run effort to lower GLP-1 prices could encourage other states to try something similar. In the meantime, you can access savings through manufacturer self pay prices, savings cards, and telehealth providers.
Can I still get semaglutide or tirzepatide if I can't afford list prices?
Often, yes. Both manufacturers now offer lower cash prices for certain doses and formats, and savings cards reduce costs for commercially insured patients. Telehealth providers with bundled pricing are another option. Check GLP-1.com's coupon page for current options.
Does Medicare cover GLP-1 medications for weight loss?
Since July 1, 2026, the temporary Medicare GLP-1 Bridge has covered Foundayo, Wegovy, and Zepbound KwikPen for weight management at $50 a month for eligible Part D enrollees who meet BMI criteria and don't have type 2 diabetes, sleep apnea, or fatty liver disease. The Bridge runs through December 31, 2027. Outside the Bridge, Part D covers GLP-1s only for approved uses like type 2 diabetes.
What is the difference between Ozempic and Wegovy for insurance purposes?
Ozempic is FDA approved for type 2 diabetes, so it is often covered when that diagnosis is present. Wegovy is FDA approved for weight management and cardiovascular risk reduction, and coverage depends on whether your plan includes obesity medications. Some insurers cover one but not the other, so check your plan's formulary directly.
What This Means for You Right Now
SB 1089 is now law, but a lower priced CalRx GLP-1 is not available yet. In the meantime, you have options available today that can make GLP-1 treatment more accessible.
Start by having an honest conversation with your doctor about your goals, your insurance situation, and what options make clinical sense for you. If your insurer has denied coverage, ask your provider about filing an appeal with a letter of medical necessity. It's more work, but it's worth trying before accepting the denial as final.
If brand name pricing is out of reach, compare manufacturer self pay prices and look at telehealth providers with bundled pricing. If you consider a compounding pharmacy, make sure it is properly licensed and works with a licensed prescriber. Check the Best Providers comparison on GLP-1.com to see which platforms offer transparent pricing and legitimate clinical oversight.
The Bigger Picture
The California story reflects a real tension. The clinical case for GLP-1 medications keeps growing, including evidence of cardiovascular benefits, but public budgets are under strain, and some states have pulled back coverage even as demand has surged. Expect more experiments with price negotiation, state manufacturing partnerships, and targeted coverage rules rather than simple mandates.
That doesn't help you if you need treatment now. But it does suggest that the cost landscape will keep shifting, and that advocating for yourself today, including appealing denials and comparing every available price option, is worth the effort.
The Bottom Line
Ozempic, Wegovy, Mounjaro, and similar GLP-1 medications have strong clinical evidence behind them. The main barrier for most patients isn't medical eligibility. It's cost.
SB 1089 is a policy effort to lower that cost, but it is narrower than a coverage mandate, it sets a goal rather than a price, and results will take time. It won't solve the national affordability problem on its own.
In the meantime, you don't have to wait. Self pay programs, savings cards, telehealth options, and provider comparisons can help you find a realistic path to treatment right now.
Explore your options with GLP-1.com. Use our GLP-1 Coupons page to find current discounts, or visit our Best Providers comparison to see which platforms offer the best combination of clinical quality and affordability. As always, work with a licensed healthcare provider before starting or changing any medication.